NCT02595866: Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms

NCT02595866
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Enrollment is not confined to only cancers strongly associated with HIV
Exclusions: Symptomatic brain metastases or the presence of leptomeningeal disease- See trial for details
https://ClinicalTrials.gov/show/NCT02595866

Comments are closed.

Up ↑